Sidapvia Dosage/Direction for Use

Posology: The recommended dose of SIDAPVIA is one dapagliflozin 10 mg/sitagliptin 100 mg tablet taken orally once daily at any time of the day, with or without food.
The tablet is to be swallowed whole.
Special Populations: Renal impairment: SIDAPVIA should not be used in patients with an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² (see Pharmacology: Pharmacokinetics under Actions). Renal function should be evaluated prior to initiation of SIDAPVIA and periodically thereafter.
Hepatic impairment: SIDAPVIA may be used in patients with mild to moderate hepatic impairment. There is limited experience in patients with severe hepatic impairment, therefore, care should be exercised when SIDAPVIA is used in this population (see Pharmacology: Pharmacokinetics under Actions).
Paediatric and adolescent patients: SIDAPVIA is not indicated for use in pediatrics and adolescent patients. Dapagliflozin and sitagliptin have not been studied in paediatric patients aged 0 to less than 18 years. Sitagliptin should not be used in children and adolescents 10 to 17 years of age because of insufficient efficacy.
Elderly patients: SIDAPVIA may be used in elderly patients. However, older patients are more likely to have impaired renal function. The renal function recommendations provided for all patients also apply to elderly patients (see Precautions).